Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas
Howard A. Fine(NYU Langone Health), Craig B. Borkowf(Center for Cancer Research), Elene Viscosi(Center for Cancer Research), Elizabeth A. Maher(Center for Cancer Research), Tracy T. Batchelor(Harvard University), Benjamin Purow(University of Virginia), Nehal J. Lakhani(Van Andel Institute), William D. Figg(National Cancer Institute), Patrick Y. Wen(Dana-Farber Brigham Cancer Center)
Cited by 174
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Malignant glioma: genetics and biology of a grave matter
|Genes & Development|2001|1.2k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k